R
Description
Respiratorius AB is a Swedish biotech company founded in 1999 as a spin-out from Lund University, headquartered in Lund. Develops candidates for the treatment of COPD, asthma and cancer. Its most advanced candidate is VAL001 (Phase III) for diffuse large B-cell lymphoma. The COPD/asthma pipeline includes RESP9000, RESP1000, RESP2000 and RCD405, with a novel mechanism of action for small airway relaxation. Collaborates with Iconovo for inhaler development. Listed on Spotlight Stock Market.